太阳娱乐娱城账号登录|首頁_欢迎您!!

关于太阳娛乐城手机游戏 About
发展历程

image.png


2019年,上海、南京、成都三地新研发中心投入运营。

In 2019, Three research centers in Shanghai, Nanjing and Chengdu established and in operating.


2018年,业务能力提升,研发管线进一步丰富。

In 2018, Internal capabilities upgraded,and R&D pipeline enriched.


2017年,数据追踪系统实现Waters网络版覆盖,年研发服务合同金额过亿。

In 2017, the Waters data online tracking system was completed, and the annual R&D service contract amount exceeded 100 million.


2016年,收购临床CRO--成都润泽医药科技开发有限公司,开启药物全流程研发服务模式。

In 2016, the company acquired the clinical CRO--Chengdu Runze Pharmaceutical Technology Development Co., Ltd., and started the drug whole process R&D service model.


2014年,第一个临床批件(奥拉西坦注射液)和第一个生产批件(乐卡地平原料药)获得批准。

In 2014, the first clinical approval (Olaracetam Injection) and the first production approval (Lecapine API) were obtained.


2012年,太阳娱乐娱城账号登录成立,开展从事药物发现,原料药及中间体研发,高端制剂研发等一系列研发服务。

In 2012, Shanghai Bocimed Pharmaceutical Co., Ltd was established to carry out a series of research and development services such as drug discovery, APIs and intermediates and high-end preparations.

COPYRIGHT 2015 太阳娱乐娱城账号登录 沪ICP备12000924号-4 本公司保留一切版权 | 条款及细 上海浦东新区松涛路647弄1号楼

沪公网安备 31011502005223号